The MYC/miR-17-92 axis in lymphoproliferative disorders: A common pathway with therapeutic potential

Michele Dal Bo, Riccardo Bomben, Luis Hernández, Valter Gattei

Research output: Contribution to journalArticle

26 Citations (Scopus)

Abstract

MicroRNAs (miRNAs) represent a class of small non-coding single-stranded RNA molecules acting as master regulators of gene expression post transcriptionally by inhibiting the translation or inducing the degradation of target messenger RNAs (mRNAs). In particular, the miR-17-92 cluster is widely expressed in many different cell types and is essential for many developmental and pathogenic processes. As a strong oncogene, miR-17-92 can regulate multiple cellular processes that favor malignant transformation, promoting cell survival, rapid cell proliferation, and increased angiogenesis. The miR-17-92 cluster has been reported to be involved in hematopoietic malignancies including diffuse large B-cell lymphoma, mantle cell lymphoma, Burkitt's lymphoma, and chronic lymphocytic leukemia. Given the multiple and potent effects on cellular proliferation and apoptosis exerted by the miR-17-92 cluster, miRNAs belonging to the cluster surely represent attractive targets for cancer therapy also in the context of lymphoproliferative disorders. In the present review, we focus on the role of the miR-17-92 cluster in lymphoproliferative disorders, including diagnostic/prognostic implications, and on the potential applications of anti-miRNAs based therapies targeting miRNAs belonging to the cluster.

Original languageEnglish
Pages (from-to)19381-19392
Number of pages12
JournalOncotarget
Volume6
Issue number23
Publication statusPublished - 2015

Fingerprint

Lymphoproliferative Disorders
MicroRNAs
Cell Proliferation
Mantle-Cell Lymphoma
Burkitt Lymphoma
Hematologic Neoplasms
B-Cell Chronic Lymphocytic Leukemia
Therapeutics
Regulator Genes
Oncogenes
Cell Survival
B-Lymphocytes
RNA
Apoptosis
Gene Expression
Messenger RNA
Neoplasms

Keywords

  • Anti-miRNA based target therapy
  • Lymphoproliferative disorders
  • miR-17-92 cluster

ASJC Scopus subject areas

  • Oncology

Cite this

The MYC/miR-17-92 axis in lymphoproliferative disorders : A common pathway with therapeutic potential. / Dal Bo, Michele; Bomben, Riccardo; Hernández, Luis; Gattei, Valter.

In: Oncotarget, Vol. 6, No. 23, 2015, p. 19381-19392.

Research output: Contribution to journalArticle

Dal Bo, Michele ; Bomben, Riccardo ; Hernández, Luis ; Gattei, Valter. / The MYC/miR-17-92 axis in lymphoproliferative disorders : A common pathway with therapeutic potential. In: Oncotarget. 2015 ; Vol. 6, No. 23. pp. 19381-19392.
@article{8da629a03e364e8d93ff344e7ce813c1,
title = "The MYC/miR-17-92 axis in lymphoproliferative disorders: A common pathway with therapeutic potential",
abstract = "MicroRNAs (miRNAs) represent a class of small non-coding single-stranded RNA molecules acting as master regulators of gene expression post transcriptionally by inhibiting the translation or inducing the degradation of target messenger RNAs (mRNAs). In particular, the miR-17-92 cluster is widely expressed in many different cell types and is essential for many developmental and pathogenic processes. As a strong oncogene, miR-17-92 can regulate multiple cellular processes that favor malignant transformation, promoting cell survival, rapid cell proliferation, and increased angiogenesis. The miR-17-92 cluster has been reported to be involved in hematopoietic malignancies including diffuse large B-cell lymphoma, mantle cell lymphoma, Burkitt's lymphoma, and chronic lymphocytic leukemia. Given the multiple and potent effects on cellular proliferation and apoptosis exerted by the miR-17-92 cluster, miRNAs belonging to the cluster surely represent attractive targets for cancer therapy also in the context of lymphoproliferative disorders. In the present review, we focus on the role of the miR-17-92 cluster in lymphoproliferative disorders, including diagnostic/prognostic implications, and on the potential applications of anti-miRNAs based therapies targeting miRNAs belonging to the cluster.",
keywords = "Anti-miRNA based target therapy, Lymphoproliferative disorders, miR-17-92 cluster",
author = "{Dal Bo}, Michele and Riccardo Bomben and Luis Hern{\'a}ndez and Valter Gattei",
year = "2015",
language = "English",
volume = "6",
pages = "19381--19392",
journal = "Oncotarget",
issn = "1949-2553",
publisher = "Impact Journals LLC",
number = "23",

}

TY - JOUR

T1 - The MYC/miR-17-92 axis in lymphoproliferative disorders

T2 - A common pathway with therapeutic potential

AU - Dal Bo, Michele

AU - Bomben, Riccardo

AU - Hernández, Luis

AU - Gattei, Valter

PY - 2015

Y1 - 2015

N2 - MicroRNAs (miRNAs) represent a class of small non-coding single-stranded RNA molecules acting as master regulators of gene expression post transcriptionally by inhibiting the translation or inducing the degradation of target messenger RNAs (mRNAs). In particular, the miR-17-92 cluster is widely expressed in many different cell types and is essential for many developmental and pathogenic processes. As a strong oncogene, miR-17-92 can regulate multiple cellular processes that favor malignant transformation, promoting cell survival, rapid cell proliferation, and increased angiogenesis. The miR-17-92 cluster has been reported to be involved in hematopoietic malignancies including diffuse large B-cell lymphoma, mantle cell lymphoma, Burkitt's lymphoma, and chronic lymphocytic leukemia. Given the multiple and potent effects on cellular proliferation and apoptosis exerted by the miR-17-92 cluster, miRNAs belonging to the cluster surely represent attractive targets for cancer therapy also in the context of lymphoproliferative disorders. In the present review, we focus on the role of the miR-17-92 cluster in lymphoproliferative disorders, including diagnostic/prognostic implications, and on the potential applications of anti-miRNAs based therapies targeting miRNAs belonging to the cluster.

AB - MicroRNAs (miRNAs) represent a class of small non-coding single-stranded RNA molecules acting as master regulators of gene expression post transcriptionally by inhibiting the translation or inducing the degradation of target messenger RNAs (mRNAs). In particular, the miR-17-92 cluster is widely expressed in many different cell types and is essential for many developmental and pathogenic processes. As a strong oncogene, miR-17-92 can regulate multiple cellular processes that favor malignant transformation, promoting cell survival, rapid cell proliferation, and increased angiogenesis. The miR-17-92 cluster has been reported to be involved in hematopoietic malignancies including diffuse large B-cell lymphoma, mantle cell lymphoma, Burkitt's lymphoma, and chronic lymphocytic leukemia. Given the multiple and potent effects on cellular proliferation and apoptosis exerted by the miR-17-92 cluster, miRNAs belonging to the cluster surely represent attractive targets for cancer therapy also in the context of lymphoproliferative disorders. In the present review, we focus on the role of the miR-17-92 cluster in lymphoproliferative disorders, including diagnostic/prognostic implications, and on the potential applications of anti-miRNAs based therapies targeting miRNAs belonging to the cluster.

KW - Anti-miRNA based target therapy

KW - Lymphoproliferative disorders

KW - miR-17-92 cluster

UR - http://www.scopus.com/inward/record.url?scp=84939226986&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84939226986&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:84939226986

VL - 6

SP - 19381

EP - 19392

JO - Oncotarget

JF - Oncotarget

SN - 1949-2553

IS - 23

ER -